Treatment of primary ciliary dyskinesia with synthetic messenger RNA
US11510997B2 · kind B2 · utility
4Cited by
3References
26Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 9, 2022 |
| Grant date | Nov 29, 2022 |
| Priority date | — |
| Expiry date | Feb 9, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N15/113
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Polynucleotides encoding peptides, proteins, enzymes, and functional fragments thereof are disclosed. The polynucleotides of the disclosure can be effectively delivered to an organ, such as the lung, and expressed within cells of the organ. The polyribonucleotides of the disclosure can be used to treat a disease or condition associated with cilia maintenance and function, impaired function of the axoneme, such as DNAI1 or DNAH5.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.